

The Generic Challenge

The Generic Challenge

Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Sixth Edition)

Martin A. Voet



BrownWalker Press
Irvine • Boca Raton

*The Generic Challenge:
Understanding Patents, FDA and Pharmaceutical Life-Cycle Management
(Sixth Edition)*

Copyright © 2004–2020 Martin A. Voet. All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law.

For permission to photocopy or use material electronically from this work, please access www.copyright.com or contact the Copyright Clearance Center, Inc. (CCC) at 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payments has been arranged.

BrownWalker Press/Universal Publishers, Inc.

Irvine • Boca Raton

USA • 2020

www.BrownWalkerPress.com

ISBN: 978-1-62734-764-4 (pbk)

ISBN: 978-1-62734-747-1 (ebk)

Typeset by Medlar Publishing Solutions Pvt Ltd, India

Cover design by Ivan Popov

Library of Congress Cataloging-in-Publication Data

Names: Voet, Martin A., 1942- author.

Title: The generic challenge : understanding patents, FDA, and pharmaceutical life-cycle management / Martin A. Voet.

Description: Sixth edition. | Irvine : Brown Walker Press, 2020. |

Includes bibliographical references and index.

Identifiers: LCCN 2020018143 (print) | LCCN 2020018144 (ebook) |

ISBN 9781627347464 (paperback) | ISBN 9781627347471 (ebook)

Subjects: LCSH: Drugs--Generic substitution--Law and legislation--United States. | Drugs--United States--Patents. | Patent extensions--United States. | Pharmaceutical biotechnology--Patents. | Pharmaceutical biotechnology--Law and legislation.

Classification: LCC KF3894.G45 V64 2020 (print) |

LCC KF3894.G45 (ebook) | DDC 346.7304/86--dc23

LC record available at <https://lcn.loc.gov/2020018143>

LC ebook record available at <https://lcn.loc.gov/2020018144>

Dedication

I would like to dedicate this Sixth Edition to my Dutch immigrant parents, Andries and Henriette Voet, who *first* had the foresight to board a boat to America in early 1939 ahead of the German invasion of Holland, thereby allowing me the privilege of being born in America; and *second*, when I was wondering what to do with myself after graduating UC Berkeley with a degree in chemistry that I did not want to pursue further, suggested that perhaps I could be a patent attorney.

*“The desire to take medicine is perhaps
the greatest feature which distinguishes man from animals”*

Sir William Osler, M.D.

Contents

Disclaimer	xv
Acknowledgments	xvii
About the Author	xix
Preface to the Sixth Edition	xxi
Preface to the First Edition	xxv
Introduction	1
Chapter 1 Overview of Patents	7
Origins of U.S. Patents	7
Is a Patent a Legal Monopoly?	8
Edison Patent for the Electric Light Bulb	9
What is a Product or Process?	9
A Patent is a Sword, Not a Shield!	14
Basic Term of a Patent	15
Harmonization	16
Submarine Patents	17
Patent Term Adjustments and Extensions	18
How are Patents Obtained?	20
First-to-invent v. First-to-file	20
Provisional Applications	22
Foreign Filings	22
Patent Cooperation Treaty (PCT)	25
Costs of Filing	26
Patent Contents	27
Specification	28
Claims Define the Scope of the Invention	28

What is Not Patentable?	32
Laws of Nature	32
Natural Substances	34
Inherency	36
Story of Aspirin	38
Basic Requirements for Patentability	38
New	39
Useful	39
Novel	40
Experimental Use Exception	40
Non-Obvious	41
Inventorship	46
Proof of Invention	47
America Invents Act	49
<i>Inter Partes</i> Review (IPR)	50
Post-expiration Patent Royalties	52
Take Home Message	53
Chapter 2 Patent Enforcement and Infringement	55
Patent Enforcement	55
Burden of Proof	56
Trials in the U.S.	57
Trials outside the U.S.	57
Patent Infringement	59
Infringement and Validity Opinions	60
To Litigate or Not to Litigate	61
Patent Strategies	62
Damages and Injunctions	63
Inducement of Infringement	64
Off-label Use Patent Infringement	65
Defenses to a Claim of Infringement	67
FDA Safe Harbor	67
Patent Exhaustion	69
Inequitable Conduct	70
Take Home Message	71

Chapter 3	Pharmaceutical, Biologic and Medical Device Patents	73
	Pharmaceutical Patents Generally	73
	Hierarchy of Pharmaceutical Patents	73
	Compound Patents	73
	Medical Use Patents	74
	Formulation Patents	75
	Biologics Patents	75
	Medical Device Patents	76
	Take Home Message	76
Chapter 4	Overview of FDA	79
	FDA Generally	79
	Origins of FDA	80
	Current FDA	81
	OGD	81
	PDUFA	82
	FDASIA	83
	Pediatric PRVs	84
	OPDP	84
	FDAMA	84
	FDARA	85
	FDA Off-label Use Issues	85
	False Claims Act	86
	FDA Orange Book	87
	Drug Industry Regulation	88
	Drug Development	88
	Pre-clinical Development	88
	Clinical Development: Phases I–IV	89
	Well-controlled Studies	89
	Accelerating NDA Approvals	90
	Types of Drug Filings	91
	Biologically Derived Drugs	92
	Antibiotics	93
	Medical Devices	93

Right-to-Try State Laws	94
Drug Agencies Outside the U.S.	95
Europe	95
Japan	97
Take Home Message	98
Chapter 5 Exclusivity for Brand Name Innovative Drug Products	101
Exclusivity in General	101
Patent Exclusivity	101
Regulatory Exclusivity	102
Orphan Drug Exclusivity	103
New Chemical Entity (NCE) Exclusivity	104
New Use/Condition of Use/Formulation Exclusivity	105
Pediatric Exclusivity	106
Qualified Infectious Disease Products (QIDP)	107
Other Forms of Exclusivity	107
Litigation Exclusivity	109
Exclusivity Outside the U.S.	109
European Union	109
Japan	112
China, Australia New Zealand and Canada	112
India	112
Take Home Message	113
Chapter 6 Generic Drugs: Hatch Waxman Act	115
Historical Background	115
The Law Today	116
FDA Orange Book	117
Patents Listed in the Orange Book	118
Patent Certifications	119
Suits Following Patent Certification	121
Therapeutic Equivalence Rating	123
Patent Use Codes	124
Litigation on the Scope of Patent Use Codes	125

180-day Generic Product Exclusivity	126
CGT Exclusivity	130
Authorized Generics	130
Medicare Act Amendments	131
Declaratory Judgment Actions	132
Counterclaim to De-list from the Orange Book	133
Agreements between Innovators and Generics	133
Settlement Agreements in Europe	137
Orphan Exclusivity to Block Generic Approval?	139
ANDA Backlog	140
Patent Challenges on the Increase	140
<i>Inter Partes</i> Review in Hatch Waxman Cases	141
Canada	142
In General	142
Paragraph IV Type Letters	143
Listing Requirements	144
NAFTA Challenge	145
Exclusivity	145
PMPRB	146
Take Home Message	147
Chapter 7 Generics for Biologic Drugs	151
Introduction	151
The Purple Book	152
Story of Erythropoietin (EPO)	152
Early Approvals of Biologic Generics	154
BPCIA	155
Biosimilars and Interchangeables	155
Exclusivity for Branded Biologics (BLAs)	157
Patent Dispute Procedures for Biosimilars	158
Biosimilar Litigation under BPCIA	158
FDA Guidance on Biosimilar Development	159
European Regulation of Biosimilars	161
Biosimilars in India and Canada	161
Take Home Message	162

Chapter 8	Putting it All Together: Product Life-Cycle Management	165
	In General	165
	FTC View: “Product Hopping”	166
	Patents	168
	Development Stage	168
	Clinical Stage	168
	Pre-approval Stage	169
	Extending the Life of Patents	170
	U.S. Patent Term Adjustments and Extensions	170
	Litigation over Patent Term Extensions	171
	Scope of Patent Term Extensions	172
	Product Improvements	172
	Active Drug Combinations	173
	Single Isomers	173
	New Dosage Forms/Delivery/Conditions of Use	174
	Orange Book Listing and De-listing	175
	Original Product Replacement	176
	Over-The-Counter (OTC) Strategy	177
	FDA Citizen’s Petitions	177
	Authorized Generics	178
	Examples of Life-Cycle Management	179
	The <i>Acular</i> (ketorolac) Story	179
	The <i>Alphagan</i> (brimonidine) Story	184
	Combigan	190
	Take Home Message	192
Chapter 9	Conclusions and Final Thoughts	193
	Drug Policy v. Industrial Policy	193
	Longer Exclusivity Terms	194
	Uniform International Approval Standards	194
	Price Controls and “free ride” Issues	195
	Prescribing Generic Drugs Even More Often	196
	Glossary of Terms	199
	Index	211

Disclaimer

This book is intended to provide information about the subject matter covered. It is sold with the understanding that the publisher and author are not engaged in rendering legal services or providing legal advice. If legal advice is required, the services of a competent legal adviser should be obtained.

Reasonable efforts have been made to make this book accurate as well as informative. However, there may be mistakes, both typographical and in content, or omissions. Therefore, this text should be used only as a general guide and is not to be relied on in any particular, keeping in mind that laws and interpretation of regulations change over time.

The purpose of this book is to educate and inform. The author and publisher shall have neither liability nor responsibility to any person or entity with respect to any loss or damage caused or alleged to be caused directly or indirectly by the information contained in this book.

The opinions expressed in this book are solely the personal opinions of the author in his individual capacity. Nothing in this book shall be attributable to the author in any representational capacity or to any other person or legal entity.

Acknowledgments

I have not attempted to cite in the text all of the authorities and sources consulted in the preparation of this book. To do so would make the book cumbersome and probably unreadable to the non-professional. Besides, I wanted to write an enjoyable book that would be easy to read and understand and by implication, that means no footnotes.

A special thanks to my long time good friend and teaching colleague, George Lasezkay, for encouraging me to write this book, whose genesis was a chapter outline sketched out on a yellow legal pad in the spring sunshine of Sun Valley, Idaho between ski runs on Baldy.

About the Author

Martin A. Voet was formerly Senior Vice President and Chief Intellectual Property Counsel for a Fortune 500 pharmaceutical company with over twenty-five years' experience in pharmaceutical intellectual property practice. He is currently a consultant in intellectual property management and pharmaceutical product exclusivity and Adjunct Professor of Law at the University of San Diego Law School.

He graduated from the University of California at Berkeley with a B.S. in Chemistry; received an M.B.A. from Pepperdine University School of Business and Management and was awarded a J.D. with Honors from the George Washington University National Law Center. He is a member of the State Bar of California.

He has been a contributor to the Practising Law Institute's *Global Intellectual Property Series* and its annual *Patent Litigation* series, contributor and member of the Editorial Board of *Managing Intellectual Property*, speaker at ACI's annual *Maximizing Pharmaceutical Patent Life Cycles* in New York and co-chaired ACI's West Coast conference on *Paragraph IV Disputes*.

He recently published an article in the American Bar Association IP Journal *Landslide Magazine* with Louis Cullman titled "*Re-Purposing and Enforcement during Patent Term Extensions for Pharma Products*", July/August 2016.

Preface to the Sixth Edition

The FDA is approving new drugs at a record pace as advances in biotechnology and genetics are enabling drug companies to obtain approvals of breakthrough drugs sooner. While the US Food and Drug Administration (FDA) approved just 22 new molecular entity (NME) drugs in 2016, it approved 46 in 2017, 59 in 2018 and 45 in 2019. In 2018, more than half the approved NMEs targeted rare (orphan) indications, three-quarters benefitted from priority review and one-quarter had breakthrough designations. Also in 2018 there were over 7,000 Investigational New Drug filings (INDs) on the FDA's books, which suggests abundant potential new drug approvals in future.

On the darker side, patient safety advocates argue that speed comes at a price and that studies show that medicines approved on a faster timeline are more likely to have safety issues after they become available or offer fewer benefits than anticipated.

While the Trump administration has focused on reducing regulations, the FDA's newfound efficiency is primarily based on user fees in return for firm deadlines and programs providing incentives for drug developers to develop products for patient groups with critical unmet needs and for rare (orphan) conditions.

Spending based on list prices of the top five brand name U.S. prescription drugs for 2018 (in *billions* of dollars) were as follows:

AbbVie's <i>Humira</i> for arthritis and psoriasis	\$19.9
BMS' and Pfizer's <i>Eliquis</i> for reducing risk of stroke	9.9
Celgene's <i>Revlimid</i> for cancer treatment	9.7
Merck's <i>Keytruda</i> for cancer immunotherapy	7.2
Amgen's <i>Enbrel</i> for arthritis and psoriasis	7.1

Note *all* of these mega-successful drugs are biotech drugs. This dramatic change of leading drugs from chemically manufactured conventional small molecule drugs to biologically produced large molecule biotech drugs is the most important current and future trend in the pharmaceutical industry. In addition, the FDA has been active in approving new “biosimilars”—essentially generic equivalents of biological drugs. In addition, FDA has published a “Biosimilars Action Plan” intended to provide clarity to biosimilar applicants on a variety of issues.

As of the end of 2019, The FDA Purple Book, which lists all approved biological drugs, now lists 24 approved biosimilars. Discounts from list prices of the branded versions of these drugs ranges from 15–33%, though market share is currently relatively small. This is in contrast with conventional drugs where generics dominate the market at substantially reduced prices once the patents on the brand name drugs have expired. This is partially a result of the fact that biosimilars are not *interchangeable* with their corresponding branded products. But from an economic point of view, the more biosimilars approved for a product, the more prices should fall. However without mandatory substitution, biosimilars will likely only capture more market share if health care professionals make the conscious decision to start new patients on the corresponding approved biosimilar.

The European Union (EU) was well ahead of the US by having approved 54 biosimilars as of 2019 for a number of important disease conditions. They currently sell for 20–30% below the list prices of the name brand versions of these drugs.

An issue you often see mentioned, especially around election time, is overcoming the high price of new drugs by importing

cheaper drugs from Canada. The U.S. Supreme Court ruled in 2017 in *Impression v. Lexmark* that any authorized sale of a patented product by the patent owner anywhere in the world exhausts all patent rights in the product sold. As a result, the patent owner can no longer enforce post sale restrictions through patent infringement suits if its patented product is sold in a foreign country. This decision should help open the legal door to importation of drugs from Canada. But that is only the beginning in this regulated world.

In late 2019, the US Department of Health and Human Services (HHS) and the FDA issued a notice of proposed rule-making and a draft guidance for the importation of certain prescription drugs—a move which would clear the way to import some prescription drugs from Canada. Also in 2019, Florida became the fourth state to pass a bill allowing for the importation of prescription drugs from Canada. This follows the Trump administration’s announcement to that effect in July of 2019. It remains to be seen if any of this will come to pass and it could take years to implement, if ever.

It is my hope that this sixth edition at the start of a new decade will be a useful update of the book as the laws and regulations and court decisions affecting this fascinating subject continue to evolve.

Martin A. Voet
March 1, 2020

Preface to the First Edition

A horse walks into a bar and the bartender says, “Why the long face?” Why indeed. The pharmaceutical industry should be on top of the world with innovative discoveries and development of so many fantastic new drugs for treating life-threatening illnesses, while often avoiding expensive surgeries. There are targeted new drugs for treating once deadly cancers and for preventing blindness; wondrous new life-saving biotech products for treating stroke and multiple sclerosis; amazing new lifestyle enhancement drugs from growing hair and erasing wrinkles to maintaining sexual vigor; yet the pharmaceutical industry is trashed nightly as being second only to the tobacco industry in the corporations-we-hate-most department.

Politicians sensing this are quick to lay blame, announce conspiracies, demand lower prices and push for re-importation of low-priced drugs from foreign countries. African countries blame them as if they started the AIDS epidemic, instead of coming up with promising treatments. Generic drugs are thought to be the answer to what is wrong with healthcare, while innovators are viewed at best with a jaundiced eye. In this charged and decidedly unfriendly environment, why write this book?

In fact there is nothing wrong with generics and they are a valuable and necessary part of a good health care system. However, there would be no generics without the innovators and I am worried that the public has lost sight of this truism. This book is intended to encourage the innovators to persevere in the